Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01710436
NCT01710436UnknownNot Applicable

Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype

Chinese Academy of Medical Sciences, Fuwai Hospital1 site in 1 country880 target enrollmentStarted: October 2012Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
880
Locations
1
Primary Endpoint
Change from Baseline in platelet aggregation
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •accept PCI in Chinese CHD patients
  • •expected dual antiplatelet therapy (DAPT) at least 6 months

Exclusion Criteria

  • •another planned PCI within 6 months

Outcomes

Primary Outcomes

Change from Baseline in platelet aggregation

Time Frame: 1 month and 6 months after PCI

Secondary Outcomes

  • Major adverse cardiovascular events (MACE); Bleeding events(6 months after PCI)

Investigators

Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xiaoxing Zhang

MD

Chinese Academy of Medical Sciences, Fuwai Hospital

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of ClopidogrelHealthy
NCT01147588AstraZeneca149
Terminated
Phase 3
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)Vascular RiskAtrial Fibrillation
NCT00243178Sanofi6,706
Completed
Phase 3
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)Vascular RiskAtrial Fibrillation
NCT00249873Sanofi7,554
Completed
Phase 1
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsHealthy
NCT03430661Viatris Innovation GmbH77
Completed
Phase 1
Investigation of Drug-drug Interaction Between Clopidogrel and FluoxetineHealthy
NCT00732290Centre Hospitalier Universitaire de Saint Etienne10